According to CDC data, those who did not receive the monkeypox vaccine had a 14 times higher risk of contracting the disease.
The effectiveness of the Jynneos vaccine against monkeypox in real-world settings has received limited research, according to CDC Director Dr. Rochelle Walensky. These new findings give us reason for hope that the vaccination is performing as intended.
Health experts, according to CNN, are upbeat about the two-dose Jynneos vaccine’s efficacy and the likelihood of ending the current outbreak in the nation.
According to a senior health official who spoke to CNN, “We are cautiously optimistic about the study and think that if we continue to provide vaccines to those who are at highest risk for disease and if we continue to promote the behavioural changes that we know work, that combination of two will allow us to continue to see decreases in cases and hopefully end the current monkeypox outbreak in the United States.”
The results don’t take into account behavioural modifications or other elements, such as the longevity of the vaccine and the potential duration of protection.
The official claimed that the system “does not allow us to properly untangle bits of this that may be behavioural change pieces that may be tied to sexual networks or to who they are coming into contact with.” “We know that many gay and bisexual males modified their habits at the beginning of the monkeypox pandemic.”
In the US, the monkeypox vaccination has been given out in doses of over 800,000. According to the CDC, 1.7 million men who have sex with other men are most at risk.
According to CDC data, the average number of new cases per day has been declining since mid-August.
